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Abstract
Aims: Vitamin K epoxide reductase complex, subunit 1 (VKORC1) is a critical participant in the production of
active forms of reduced vitamin K and is required for modification of vitamin K–dependent proteins. Homologues
of VKORC1 (VKORH) exist throughout evolution, but in bacteria they appear to function in oxidative protein
folding as well as quinone reduction. In the current study we explore two questions: Do VKORHs function in the
mammalian vitamin K cycle? Is the pair of loop cysteines—C43 and C51 in human VKORC1—conserved in all
VKORC1s, essential for the activity of vitamin K epoxide reduction? Results: We used our recently developed cell-
based assay to compare the function of VKORHs to that of human VKORC1 in mammalian cells. We identified for
the first time a VKORH (from Mycobacterium tuberculosis [Mt-VKORH]) that can function in the mammalian
vitamin K cycle with vitamin K epoxide or vitamin K as substrate. Consistent with our previous in vitro results, the
loop cysteines of human VKORC1 are not essential for its activity in vivo. Moreover, the corresponding loop
cysteines of Mt-VKORH (C57 and C65), which are essential for its activity in disulfide bond formation during
protein folding in Escherichia coli, are not required in the mammalian vitamin K cycle. Innovation and Conclusions:
Our results indicate that VKORC1 in eukaryotes and Mt-VKORH in bacteria, that is, in their respective native
environments, employ apparently different mechanisms for electron transfer. However, when Mt-VKORH is in the
mammalian cell system, it employs a mechanism similar to that of VKORC1. Antioxid. Redox Signal. 16, 329–338.
Introduction
Vitamin K epoxide reductase complex, subunit 1(VKORC1) is an endoplasmic reticulum (ER) integral
membrane protein (18, 23). It is responsible for the conversion
of vitamin K epoxide (KO, a quinone epoxide) to vitamin K (a
quinone), and can also convert vitamin K to vitamin K hy-
droquinone (KH2). This series of quinone reductase reactions
is an essential part of a redox cycle known as the vitamin K
cycle (3). The active form of the vitamin, KH2, is a cofactor for
posttranslational modification of proteins essential for blood
coagulation, bone homeostasis, signal transduction, and cell
proliferation (6, 29).
VKORC1 is a member of a large family of homologues
(VKORH) widely distributed among vertebrates, inverte-
brates, plants, bacteria, and archaea (12). All of these enzymes
are quinone reductases, but in bacteria they also participate in
disulfide bond formation during protein folding. The signifi-
cance of VKORC1’s role in the latter process in eukaryotes
remains unclear (33). In bacteria, VKORHs are present espe-
cially in strains lacking the quinone reductase, DsbB (7). At
least some of the bacterial VKORHs can complement DsbB in
Escherichia coli DsbB deletion mutant strains (7, 27, 35).
DsbB and VKORHs have two pairs of conserved cysteines
that are necessary for catalysis (30, 36): the active site, CXXC,
which reduces ubiquinone and a second pair, the loop cys-
teines, which oxidizes DsbA to its active form (16). In DsbB the
loop cysteines shuttle electrons from DsbA to reduce the
disulfide-bonded CXXC to free cysteines. In vitro enzymatic
activity assays and cell-based E. coli complementation studies
show that all four conserved cysteine residues in bacterial
VKORH are required for activity (19, 35). Based on these re-
sults, an intramolecular electron transfer pathway between
the two pairs of conserved cysteines, similar to that of DsbB,
has been proposed for the bacterial VKORHs as well as for
mammalian VKORC1 (19, 25).
While the electron flow in DsbB is well established, the
mechanism for active site regeneration in VKORC1 is less
clear. Experimental data from site-directed mutagenesis con-
firm that two conserved cysteine residues, C132 and C135,
comprise the CXXC redox center in human VKORC1 (15, 22,
34). But reports of the function of the other pair of conserved
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loop cysteine residues, C43 and C51, do not allow a consistent
interpretation for their role (15, 21, 22). It appears that
VKORC1’s active site can be reduced in at least two ways.
Results with thioredoxin (Trx)/Trx reductase as reductant
suggest that the loop cysteines are important for activity (21).
On the other hand, with dithiothreitol (DTT) as reductant the
loop cysteines do not appear to be essential (15, 22, 34). This
latter observation is also true with the Synechococcus VKORH
(19). This would indicate that the active site can be reduced
directly by DTT or by the loop cysteines that accept electrons
from a physiologic reductant.
Although DsbB, VKORH, and VKORC1 are functionally
similar enzymes, there is limited sequence identity among them.
The DsbB has almost no identity with the others. VKORC1 and
VKORHs have amino acid identity between 20% and 25%. In-
terestingly, the sequence identities among the VKORHs are as
divergent as those among VKORHs and VKORC1; for example,
Synechococcus VKORH and Mycobacterium VKORH are 20%
identical and both are *20% identical to human VKORC1. This
is important for at least two reasons. First, residues conserved
among VKORC1s and VKORHs are candidates for functional
importance. On the other hand, the low similarity would sug-
gest that the tertiary structure could be significantly different,
and therefore results with either group should be interpreted
carefully when applied to the other.
In addition, there appear to be significant differences in the
reactions the VKORH versus VKORC1 catalyze. While the
VKORH oxidation of DsbA, as well as quinone reduction, is
essential for protein folding and electron transport, it is not
obvious that VKORC1’s participation in any function other
than the vitamin K cycle, and quinone reduction, is essential
in the eukaryotic system. If this were not the case, then it
seems that drugs such as warfarin, a VKORC1 inhibitor,
would cause widespread physiologic changes unrelated to
the known functions of vitamin K.
Recently we described a cell-based assay that allows us to
study the mammalian vitamin K cycle in the cellular milieu
(31). This approach has the advantage of allowing us to as-
sess functionality of VKORC1 or a homologue in an envi-
ronment that requires the enzyme to interact with its
physiologic reduction partner and other in vivo components
of the vitamin K cycle. We use two cell lines for the experi-
ments depending on the question we are asking. The
HEK293 cells have endogenous KO to vitamin K (VKOR)
activity that is warfarin sensitive and vitamin K to KH2
(VKR) activity that is warfarin resistant. On the other hand,
AV12 cells do not have warfarin-resistant enzyme(s) for
VKOR or VKR activity. These cell lines are, therefore, a
useful tool for expressing warfarin-resistant VKORC1 or
its homologues for studying either VKOR or VKR activity
depending on whether we supply KO or vitamin K as
substrate.
Taking advantage of this assay system, in our current study,
we expressed five VKORHs in HEK293 and AV12 cell lines. We
then determined whether any of these enzymes could function
in the mammalian vitamin K cycle leading to carboxylation of a
chimeric reporter protein, protein C, with its gla domain ex-
changed with factor IX (FIXgla-PC) (31). We hoped that if a
given homologue is active then we will be able to find clues as to
the features in VKORC1 important for its function. In addition,
we extended our earlier in vitro studies concerning the roles of
the loop cysteines in VKORC1 to this in vivo assay. The results
indicate that at least three bacterial homologues of VKORC1 can
support carboxylation. Interestingly these enzymes are warfa-
rin resistant and have both VKOR and VKR activity. Finally in
our cell-based assay system, the loop cysteines are not essential
for activity of VKORC1 or the Mt-VKORH.
Results
Investigation of VKORHs’ ability to support in vivo
carboxylation with KO as substrate
Some VKORH have certain structural and functional
characteristics similar to those of human VKORC1 (19, 25).
We used our cell-based assay to investigate whether these
similarities allow some VKORHs to participate in the mam-
malian vitamin K cycle. We initially tested VKORHs from
three organisms (Fig. 1A): Synechococcus sp. (Ss-VKORH),
which has VKR activity and a Trx-like domain at its C-ter-
minus and whose crystal structure has been reported (19);
Roseiflexus sp. RS-1 (Rs-VKORH), which has an N-terminal
Trx-like domain; and Mycobacterium tuberculosis (Mt-
VKORH), which has no Trx-like domain but is active in E. coli
protein folding and is reported to be warfarin sensitive (8). We
transiently expressed these enzymes in HEK293 cells that
stably express the reporter protein and cultured the cells in the
presence of 5 lM KO and 4 lM warfarin. The HEK293 cells
have warfarin-resistant VKR activity, but warfarin-sensitive
VKOR activity. Therefore, the carboxylated reporter protein
can result only if the exogenously expressed VKORH has
warfarin-resistant VKOR activity. Of the VKORH tested, only
Mt-VKORH supported carboxylation of the reporter protein
(Fig. 1B). Mt-VKORH has 2.5-fold higher activity than human
VKORC1-Y139F. Since VKORC1-Y139F has *40% of wild-
Innovation
Vitamin K epoxide reductase complex, subunit 1
(VKORC1) is an enzyme of the endoplasmic reticulum that
supports posttranslational modification of glutamate to 4-
carboxy glutamate of numerous proteins whose impor-
tance spans several physiologic areas including blood co-
agulation, bone metabolism, and signal transduction.
VKORC1 is a member of a widely distributed family of
enzymes found throughout evolution. Characterizations
of the human enzyme and homologues from bacteria have
yielded a large amount of structure–function information,
but some are contradictory. This is particularly true of re-
sults about the role of the conserved loop cysteines as well
as the membrane structure. In the current study, we used
our recently developed cell-based assay to compare the
function of homologues of VKORC1 (VKORHs) to that of
human VKORC1 in mammalian cells. We identified for the
first time a VKORH (from Mycobacterium tuberculosis [Mt-
VKORH]) that can function in the mammalian vitamin K
cycle. Moreover, the conserved loop cysteines of Mt-
VKORH, which are essential for electron transfer in dis-
ulfide bond formation during oxidative protein folding in
Escherichia coli, are not required in the mammalian vitamin
K cycle. Our results indicate that VKORC1 and VKORH in
their native milieu employ fundamentally different
mechanisms in quinone reduction. However, in mamma-
lian cells they employ a similar mechanism.
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type activity (17, 24), this result suggests that Mt-VKORH has
activity similar to that of wild-type human VKORC1.
To confirm that VKORHs that lack activity are actually
expressed and targeted to the correct cellular location, we
fused a HPC4 epitope (peptide epitope from human protein C
comprising residues EDQVDPRLIDGK) tag or a green fluo-
rescence protein (GFP) tag at the C-terminus of these proteins.
Western blot results show that Rs-VKORH and Ss-VKORH,
which are inactive in the cell-based assay, are expressed at a
level similar to those of VKORC1-Y139F and Mt-VKORH
(Fig. 2A). Confocal fluorescence microscopy results show that
when GFP alone is expressed, it is present throughout the cell
(Fig. 2B). However, like the VKORC1-Y139F-GFP fusion, all
the VKORH-GFP fusions appear to reside in the ER mem-
brane; thus, the subcellular location of the three VKORHs
tested is similar to that of VKORC1.
Reduction of vitamin K to KH2
by VKORHs in AV12 cells
Since HEK293 cells have an unidentified warfarin-resistant
vitamin K reductase (26, 31), the results presented in the
previous section with HEK293 cells indicate only that Mt-
VKORH can reduce KO to vitamin K. In contrast to HEK293
cells, AV12 cells have almost no warfarin-resistant vitamin K
reductase (31), and in the presence of warfarin, they produce
no carboxylated reporter protein. Previously we showed
that VKORC1-Y139F can efficiently catalyze the VKOR but
not the VKR reaction to an extent necessary for efficient car-
boxylation. Thus, AV12 cells stably expressing VKORC1-
Y139F are a good model for investigating the ability of an
exogenous enzyme’s ability to reduce vitamin K to KH2 (31).
FIG. 1. Reduction of KO to vitamin K by VKORHs to
support carboxylation in HEK293 cells. (A) Schematic rep-
resentation of the VKORHs and controls used in this study.
The solid bars indicate the TMD predicted by TOPCONS (4)
or experimentally determined TMD for human VKORC1 (32)
and DsbB (14). The gray bars indicate the Trx-like domain.
The alignment of VKORHs is based on the TMD-containing
CXXC redox center. (B) Cell-based activity assay of VKORHs
to reduce KO to vitamin K. VKORHs and controls (warfarin-
resistant human VKORC1-Y139F and DsbB) were transiently
expressed in FIXgla-PC/HEK293 cells. Cells were cultured in
complete medium containing 5 lM KO and 4 lM warfarin
for 48 h. The concentration of carboxylated FIXgla-PC in the
cell culture medium was measured by ELISA and normal-
ized by luciferase activity as described in the Materials and
Methods section. Data are presented as mean – SD (n = 3).
*p < 0.001, compared with human VKORC1-Y139F. FIXgla-
PC, protein C with its gla domain exchanged with factor IX;
VKORC1, vitamin K epoxide reductase complex, subunit 1;
VKORHs, homologues of VKORC1; Trx, thioredoxin; TMD,
transmembrane domain.
FIG. 2. Expression and subcellular location of VKORC1
and its homologues in HEK293 cells. (A) Western blot de-
tection of the expression of VKORC1 and its bacterial homo-
logues in HEK293 cells. HPC4-tagged proteins were transiently
expressed in HEK293 cells for 48 h. Cell lysates were directly
used for SDS-NuPAGE and protein bands were transferred to
PVDF membrane. HPC4-tagged protein bands were probed
with anti-HPC4 monoclonal antibody and visualized by ECL
Western blot reagents. Lane 1, VKORC1-Y139F; lane 2, Mt-
VKORH; lane 3, Rs-VKORH; lane 4, Ss-VKORH; M, marker,
kDa. (B) Subcellular localization of VKORC1 and its bacterial
homologues in HEK293 cells. GFP-tagged proteins were tran-
siently expressed in HEK293 cells for 48 h. Cell images were
collected from emission at 493–530 nm after excitation at
488 nm. GFP, green fluorescence protein; HPC4, peptide epi-
tope from human protein C comprising residues EDQVDPR-
LIDGK; Rs-VKORH, Roseiflexus sp. RS-1 vitamin K epoxide
reductase homologue; SDS-NuPAGE, Sodium dodecyl sulfate
neutral polyacrylamide gel electrophoresis; Ss-VKORH, Sy-
nechococcus sp. vitamin K epoxide reductase homologue.
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To determine whether VKORHs can efficiently reduce vi-
tamin K to KH2, and thus supports carboxylation, we tran-
siently expressed the VKORHs in FIXgla-PC/AV12 cells
stably expressing VKORC1-Y139F. As described in the pre-
vious paragraph, if we introduce an enzyme that can effi-
ciently reduce vitamin K to KH2, the resulting cell line should
produce carboxylated reporter protein when the cells are
cultured with KO and warfarin. Of the cell lines transiently
expressing VKORHs, only those expressing Mt-VKORH and
Rs-VKORH have significant activity (Fig. 3A). VKORH from
Synechococcus can reduce vitamin K in vitro (10, 19), but it has
no significant activity in our in vivo system.
To further confirm that Mt-VKORH can reduce both KO to
vitamin K and vitamin K to KH2, we transiently expressed
either Mt-VKORH or VKORC1-Y139F in FIXgla-PC/AV12
cells that were not expressing VKORC1-Y139F. We cultured the
cells in 5 lM KO and 4 lM warfarin. Since in AV12 cells war-
farin inhibits both the VKOR and VKR endogenous activities,
we reasoned that only cells with an exogenously expressed
enzyme that can reduce both KO and vitamin K will produce
carboxylated reporter protein. As we showed in our previous
publication, expression of VKORC1-Y139F did not support
carboxylation of the reporter protein (31). In contrast, expression
of Mt-VKORH produced significant carboxylated reporter pro-
tein (Fig. 3B). This result further supports the conclusion that Mt-
VKOKH can reduce both KO and vitamin K. It also supports our
earlier conclusions that the main function of human VKORC1
in the vitamin K cycle is to reduce KO to vitamin K (31).
The effect of cysteine mutations on Mt-VKORH
ability to support in vivo carboxylation
In order to examine the role of cysteine residues in Mt-
VKORH’s function in the vitamin K cycle, we used HEK293
cells stably expressing the reporter protein. In that cell line, we
transiently expressed mutant Mt-VKORH with conserved
cysteines changed to alanine (C57A, C65A, C139A, C142A,
and C57A/C65A). The cells were then cultured in the pres-
ence of 5 lM KO and 4 lM warfarin. Mutation of either of the
cysteines (C139 or C142) in the CXXC redox center abolishes
its ability to support carboxylation (Fig. 4). These mutations
also abolish the ability of Mt-VKORH to complement DsbB
deletion in E. coli (35). Mt-VKORH C57A mutant has < 10%
carboxylation activity (Fig. 4). On the other hand, C65A and
C57A/C65A mutants retain 50%–70% activity of the wild-
type Mt-VKORH. Since mutation of either C57 or C65 abol-
ishes Mt-VKORH activity for complementing DsbB in E. coli
and is absolutely required for its activity (35), this result
suggests that loop cysteines C57/C65 are not essential for the
reduction of KO in mammalian cells.
The effect of cysteine mutations on human
VKORC1 activity in vivo
We previously reported that only the CXXC active site
cysteines are essential for human VKORC1 activity by the
in vitro assay (15). In that study we used purified VKORC1
and its cysteine mutants. In the current study, to test these
same VKORC1 mutants in vivo, we employed the cell-based
assay using the same cell system described in the previous
paragraph. To accomplish this, we changed the cysteines to
alanines in the warfarin-resistant VKORC1-Y139F molecule
and transiently expressed these enzymes in FIXgla-PC/
HEK293. The in vivo results (Fig. 5A) are similar to our pre-
vious in vitro results except that the C16A and C96A muta-
tions have 75%–100% activity in the in vivo assay but have
only *40% activity in the in vitro assay. One possible reason
for the activity difference could be the lipid composition dif-
ferences between the in vitro and in vivo assays since both C16
and C96 are located in a hydrophobic region. Another
FIG. 3. Reduction of vitamin K to KH2 by VKORHs to
support carboxylation in AV12 cells. (A) VKORH from
different species was transiently expressed in FIXgla-PC/
VKORC1-Y139F/AV12 cell line and the enzymatic activity
was determined as described in the legend of Figure 1. Data
are presented as mean – SD (n = 3). *p < 0.001, compared with
Mt-VKORH. (B) Warfarin-resistant human VKORC1-Y139F
and Mt-VKORH were transiently expressed in the FIXgla-
PC/AV12 cell line and the enzymatic activity was deter-
mined as described in the legend of Figure 1. Data are pre-
sented as mean – SD (n = 3). *p < 0.01, compared with human
VKORC1-Y139F. KH2, vitamin K hydroquinone.
FIG. 4. Reduction of KO to vitamin K by Mt-VKORH
cysteine mutants to support carboxylation in HEK293 cells.
Mt-VKORH and its cysteine mutants were transiently ex-
pressed in FIXgla-PC/HEK293 cells and the enzymatic ac-
tivity was determined as described in the legend of Figure 1.
The control is transfection of the expression vector into the
above cell line. Data are presented as mean – SD (n = 3).
*p < 0.001, compared with control.
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possibility for the lower activity in the in vitro assay could be
part of the purified enzyme is inactive because the mutation of
cysteine renders the molecule less stable in vitro.
Only mutations of the active site residues, C132 and C135,
reduce activity to background levels. The C43A has *30%
activity in the in vitro assay but *5% activity in the in vivo
assay. The C51A has activity similar to that of wild-type
VKORC1 in both assays. To confirm the role of C43 and C51,
we mutated both the cysteines to alanine, or deleted both the
cysteines and the sequences between them. As shown (Fig.
5B), in either case, the molecule still retains *60% activity. In
addition, mutating all five nonactive site cysteines simulta-
neously to alanine results in a molecule with *40% activity.
These results together suggest that the conserved loop cyste-
ines, C43 and C51, are not required for VKOR activity, which
agrees with our previous in vitro results (15).
Cysteine residues 57 and 65 of Mt-VKORH
are located in the ER lumen
Membrane topology studies of Mt-VKORH in E. coli indi-
cate that C57 and C65 are located in the periplasm, the same
side of the bacterial inner membrane as the CXXC redox
center (35). A similar membrane topology has been proposed
for human VKORC1 (19, 25). However, our previously pub-
lished in vitro results and our recent in vivo studies (unpub-
lished results) place the corresponding conserved pair of
cysteines 43 and 51 of human VKORC1 in the cytoplasm. If
true this means that these cysteines are on the opposite side of
the ER membrane from the CXXC redox center (32) (Fig. 6A).
The function of C57 and C65 of Mt-VKORH in reducing KO in
mammalian cells appears to be similar to that of C43/C51 of
human VKORC1, but different than its function for DsbB
complementation in E. coli. One reason for this might be that
Mt-VKORH has a different membrane topology in E. coli than
in mammalian cells.
To test this possibility, we used the N-linked glycosylation
mapping technique (5) to determine the Mt-VKORH mem-
brane topology in HEK293 cells. Our results show that in-
troducing glycosylation sites between the conserved loop
cysteines or at the C-terminus of the molecule causes Mt-
VKORH to migrate slower than wild-type enzyme in sodium
dodecyl sulfate neutral polyacrylamide gel electrophoresis
(SDS-NuPAGE) (Fig. 6B, lanes 3 and 5). These higher-
molecular-weight molecules are sensitive to endoglycosidase
digestion (Fig. 6B, lanes 4 and 6), indicating that the intro-
duced sites are glycosylated. Therefore, the cysteine pair C57/
C65 and the C-terminus of Mt-VKORH are located in the ER
lumen, which is consistent with the periplasmic location in
bacteria (35). Glycosylation at the C-terminus does not affect
Mt-VKORH activity, while glycosylation in the loop between
C57 and C65 decreases activity 50% compared with that of the
wild-type enzyme (Fig. 6C). This result, together with the
cysteine mutation results of human VKORC1 (Fig. 5), further
suggests that whether the conserved loop cysteine pair is
located in the cytoplasm or ER lumen, they are not required
for the reduction of the CXXC redox center.
Reduction of KO and vitamin K by other bacterial
VKORHs with sequences similar to that of Mt-VKORH
Our results suggest that VKORHs without the Trx domain
may be more likely to catalyze both the reduction of KO and
vitamin K. In contrast to VKORC1, the dipeptide sequence
between the active site cysteines in Mt-VKORH is PY, which is
a common sequence in the glutaredoxin family’s CXXC redox
center. The PY sequence causes a pKa < 4 for the N-terminal
nucleophilic cysteine and a high reducing potential (11).
Therefore, the dipeptide PY may also contribute to VKOR and
VKR activity. To test this hypothesis, we selected two bacte-
rial VKORHs with higher sequence identity (35%–50%) to
Mt-VKORH and PY as the dipeptide: Cj-VKORH (from Cor-
ynebacterium jeikeium K411) and St-VKORH (from Salinispora
tropica CNB-440). With KO as substrate, St-VKORH and
FIG. 5. Reduction of KO to vitamin K by VKORC1 cys-
teine mutants to support carboxylation in HEK293 cells. (A)
Individual cysteines in warfarin-resistant VKORC1-Y139F
were mutated to alanine. These mutant proteins were tran-
siently expressed in FIXgla-PC/HEK293 cells and the enzy-
matic activity was determined as described in the legend of
Figure 1. The results are shown as black bars with the Y-axis
on the left. The VKORC1-Y139F activity was normalized to
100%. The gray bars represent our previous in vitro results
(15). Wild-type VKORC1 activity was normalized to 100%.
(B) Activity assays of the double mutation C43A and C51A
(C43/51A), deletion of these two cysteines and the residues
between them (C43-51-DEL), and mutation of five cysteines
(C16A, C43A, C51A, C85A, and C96A) simultaneously
(5C-Mut). Data are presented as mean – SD (n = 3). *p < 0.05,
**p < 0.001, compared with VKORC1-Y139F. {p < 0.05,
{{p < 0.001, compared with the in vitro results.
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Cj-VKORH have 30% and 70% activity relative to Mt-
VKORH, respectively (Fig. 7A). To determine whether these
enzymes can reduce vitamin K to KH2 to support carboxyla-
tion, we expressed them in FIXgla-PC/VKORC1-Y139F/
AV12 cell lines. As is the case with Mt-VKORH, these two
VKORHs also have significant VKR activity (Fig. 7B).
Discussion
Characterizations of the human VKORC1 and its homo-
logues from bacteria and plants have yielded important
structure–function information about this family of enzymes
(7, 8, 19, 27, 35). We are primarily interested in how the human
VKORC1 functions in the mammalian vitamin K cycle, and
how it interacts with the other components of that cycle.
Identifying apparent functional differences and similarities
among the various homologues should shed light on the
significance of structural differences. The problem is that
comparing the results until now has been difficult because the
studies were done using a variety of experimental models. We
believe that studying VKORC1 and its homologues in the
same in vivo system provides valuable insights toward our
goal of understanding structure–function relationships in
VKORC1. Our objective in the current study was to use our
previously described cell-based assay (31) to identify simi-
larities and differences of function between VKOR homo-
logues and VKORC1.
Initially we investigated three bacterial VKORHs (Mt-
VKORH, Ss-VKORH, and Rs-VKORH), one of which, Ss-
VKORH, has been shown to reduce vitamin K in vitro (2,
13). We set out to investigate whether these enzymes could
participate in the mammalian vitamin K cycle and support
carboxylation in vivo. We had previously shown that,
FIG. 6. Localization with respect to
the ER membrane of the conserved
loop cysteines 57 and 65 and the C-
terminus of Mt-VKORH by N-linked
glycosylation mapping. (A) Schematic
representation of the proposed mem-
brane topology of human VKORC1
(32) and Mt-VKORH (35). Conserved
loop cysteines are indicated by black
dots and Y indicates the introduced N-
linked glycosylation site. The CXXC
redox center is located near the N-ter-
minus of the third TMD in human
VKORC1 and the fourth TMD in
Mt-VKORH; both face the ER lumen.
(B) Localization of the introduced
glycosylation site in Mt-VKORH by
Western blot assay. HPC4-tagged Mt-
VKORH (WT) and its glycosylation
mutants (NST60: glycosylation site was
introduced between cysteine 57 and
65; NSTend: glycosylation site was in-
troduced at the C-terminus) were
transiently expressed in HEK293 cells.
Cell lysate was treated with or without
PNGase F before being subjected to SDS-NuPAGE. HPC4-tagged protein bands were probed with anti-HPC4 monoclonal
antibody and visualized by ECL Western blot reagents. (C) Cell-based activity assay of Mt-VKORH glycosylation mutants.
Mt-VKORH and its glycosylation mutants were transiently expressed in FIXgla-PC/HEK293 cells and the enzymatic activity
was determined as described in the legend of Figure 1. Data are presented as mean – SD (n = 3). *p < 0.001, compared with
wild-type Mt-VKORH. ER, endoplasmic reticulum.
FIG. 7. VKOR and VKR activity assay of bacterial
VKORHs with sequences similar to Mt-VKORH. (A) Cell-
based VKOR activity assay of Cj-VKORH and St-VKORH
in FIXgla-PC/HEK293 cells. VKORHs were transiently ex-
pressed in FIXgla-PC/HEK293 cells and the enzymatic ac-
tivity was determined as described in the legend of Figure 1.
(B) Cell-based VKR activity assay of the same bacterial
VKORHs as in (A) in FIXgla-PC/VKORC1-Y139F/AV12
cells. VKORHs were transiently expressed and the enzymatic
activity was determined as described in the legend of Figure 1.
Data are presented as mean – SD (n = 3). *p < 0.05, **p < 0.001,
compared with Mt-VKORH. Cj-VKORH, Corynebacterium
jeikeium vitamin K epoxide reductase homologue; St-VKORH,
Salinispora tropica vitamin K epoxide reductase homologue;
VKOR, the reduction of vitamin K epoxide to vitamin K; VKR,
the reduction of vitamin K to KH2.
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while VKORC1 can support VKR reaction in vitro, in our
cell-based system, human VKORC1-Y139F does not sup-
port the reduction of vitamin K efficiently enough for re-
porter protein carboxylation (31). According to our results,
of the three VKORHs tested, only Mt-VKORH can employ
KO in mammalian cells to support carboxylation of our
reporter protein (Fig. 1). But with vitamin K as substrate,
both Mt-VKORH and Rs-VKORH (although to a lesser
extent) can support carboxylation (Fig. 3). This result is
particularly interesting. First, Mt-VKORH is the only
noneukaryotic enzyme shown to reduce KO to vitamin K;
second, as opposed to VKORC1, it efficiently uses either
KO or vitamin K as substrate; third, the Mt-VKORH is
resistant to warfarin at concentrations that completely in-
hibit VKORC1 in our system; and finally, the active sites of
both Mt-VKORH can be reduced in vivo by the physiologic
reductant for VKORC1.
Mt-VKORH’s activity in the DsbB complementation assay
in E. coli requires both the active site (CPYC) cysteines and
the loop cysteines (C57 and C65). Mutations of any of these
four cysteines abolish Mt-VKORH activity (35). In contrast,
our results indicate that, like VKORC1 (Fig. 5), only the ac-
tive site cysteines are required for Mt-VKORH function in
mammalian cell carboxylation (Fig. 4). Although in both
enzymes mutation of the first loop cysteine (C57 in Mt-
VKORH or C43 in VKORC1) significantly decreases VKOR
activity, mutation of the second loop cysteine (C65 in Mt-
VKORH or C51 in VKORC1) or of both loop cysteines has a
minor effect on VKOR activity (Fig. 5). These results are
consistent with those presented in our earlier publication
with purified VKORC1 (15).
One possible explanation for these results is that the first
loop cysteine (C57 and C43) in both enzymes is absolutely
required for electron transfer. It could form a mixed disulfide
with one of the active site (CXXC) cysteines. In the wild-type
enzyme, the second loop cysteine (C65 and C51) would then
reduce this mixed disulfide to activate the enzyme. If this
hypothesis was correct, then mutating C57 or C43 would
prevent the formation of the mixed disulfide and inactivate
the enzyme. On the other hand, with the C65 or C51 mutant,
perhaps the mixed disulfide is reduced by an unidentified
intracellular component to reactivate the enzyme’s CXXC. If
this is the case, one would expect that when the active site is
directly reduced by a reductant, such as DTT, mutating the
loop cysteines should not affect the activity. Our results
show that with either DTT (in vitro results) or the physio-
logical reductant (in vivo results) the C43A VKORC1 mutant
has significantly decreased activity (Fig. 5). This suggests
that the mixed disulfide pathway does not apply to the
VKORC1 reduction of KO. Since we do not have in vitro
results for Mt-VKORH, we cannot rule this mechanism out
for Mt-VKORH. However, the loop cysteine mutants of Ss-
VKORH do have full activity with DTT as reductant in the
in vitro assay where the mixed disulfide mechanism apply
(19). As proposed previously (22), an alternative explanation
for the significant activity decrease caused by the C43A
mutant is that it is important for maintaining the active en-
zyme structure.
While the membrane topology of human VKORC1 is con-
troversial (19, 32), according to our previous results, the hu-
man VKORC1 has three transmembrane domains (TMDs)
(32) and the loop cysteines are in the cytoplasm. On the other
hand, according to Wang et al. the VKORC1 domain of Mt-
VKORH has four TMDs (35) with the loop cysteines located in
the periplasm of E. coli - which is analogous to the ER lumen in
eukaryotic cells. Since the loop cysteines of Mt-VKORH are
essential for activity in E. coli, but not in our mammalian
system, it is conceivable that a different location of the loop
cysteine in E. coli and mammalian cell might contribute to this
difference. Our results show this is not the case (Fig. 6); con-
sistent with the E. coli results the loop cysteines are in the ER
lumen. This result indicates that there are at least two mech-
anisms by which the active site of the reductases can be
reduced.
In the bacteria periplasm, the loop of the VKORH interacts
with DsbA to support disulfide bond formation during fold-
ing of proteins necessary for cell motility. This leaves the loop
cysteines in the sulfhydryl form so they can in turn reduce the
active site CXXC to activate VKORH for quinone reduction.
On the other hand, in the mammalian system, the loop of
VKORC1 or VKORH apparently plays only a secondary role
in any reducing cycle other than that of vitamin K. If this was
not the case, it seems likely that warfarin inhibition of the
enzyme might affect important cellular functions other than
vitamin K production and cause negative physiological ef-
fects. In addition, if this was not the case, the murine knockout
of VKORC1 would not be viable when fed with vitamin K
(28). This suggests that in the mammalian system reduction of
the active site CXXC must be catalyzed directly and inter-
molecularly by an as yet unidentified reducing protein/mol-
ecule (Fig. 8).
In addition to shedding light on the role of cysteines in the
mammalian vitamin K cycle, our results show that VKORHs
lacking Trx-like domains (Mt-VKORH, St-VKORH, and Cj-
VKORH) can support carboxylation utilizing both KO and
vitamin K. This indicates that in our system the Trx-like do-
main is not necessary for either the VKOR or VKR reaction.
We believe that sequence differences and similarities among
these enzymes will lead to identification of structural features
that contribute to the functional differences and likely lead to
a better understanding of structure–function in VKORC1.
In summary, we have shown that VKORH from M. tuber-
culosis, C. jeikeium, and S. tropica can reduce both KO and
vitamin K to support carboxylation in mammalian cells. In
contrast to Mt-VKORH’s function in oxidative protein folding
in E. coli, the conserved loop cysteines are apparently dis-
pensable for supporting carboxylation in mammalian cells. If
the three TMD structures of human VKORC1 are correct, then
our results with Mt-VKORH suggest that as long as the active
site of the enzyme is facing the lumen of the ER, the location of
the loop cysteines does not affect activity in the vitamin K
cycle. These results indicate that Mt-VKORH can function by
two physiologically relevant mechanisms depending on its
cellular environment. Based on comparison of VKORHs’ se-
quences to that of the VKORC1, our results should also pro-
vide a platform for identifying residues in VKORC1 that are
likely important for its function.
Materials and Methods
Materials
Vitamin K1 and warfarin were obtained from Sigma-
Aldrich (St. Louis, MO). Luciferase substrate coelenterazine
was from NanoLight Technology (Pinetop, AZ). Mammalian
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expression vector pIRES2 DsRed-Express2, secreted Metridia
luciferase containing vector pBI-CMV5, and Xfect transfection
reagent were from Clontech Laboratories, Inc. (Mountain
View, CA). HEK293 and AV12 cell lines were from ATCC
(Manassas, VA). All cell culture medium were from Invitro-
gen Corp. (San Diego, CA). The cDNA sequences coding the
VKORHs and DsbB used in the study were optimized for
mammalian cell expression and chemically synthesized by
Blue Heron Biotechnology (Bothell, WA). Mouse antic-
arboxylated factor IX gla domain monoclonal antibody (BC2)
was a gift from GlaxoSmithKline (Philadelphia, PA) and
Green Mountain Antibodies (Burlington, VT) (1, 9). Horse-
radish peroxidase–conjugated affinity purified sheep antihu-
man Protein C IgG was from Affinity Biologicals, Inc.
(Ancaster, ON Canada). Anti-HPC4 monoclonal antibody
was from Dr. Charles T. Esmon (Oklahoma Medical Research
Foundation, Oklahoma City, OK).
DNA manipulations and plasmid constructions
Mammalian expression vector pIRES2 DsRed-Express2
was used as the basic cloning vector. The red fluorescent
protein DsRed-Express2 was replaced by secreted Metridia
luciferase that was used as the internal control for normaliz-
ing the transient transfection efficiency. The resulting vector
pIRES2-Met.Luc was used for expressing all the molecules
used in this report. This vector permits both the target protein
and the secreted Metridia luciferase to be translated from a
single mRNA transcript with a ribosome re-entry site.
All VKORHs and warfarin-resistant human VKORC1
(Y139F) and their mutants were subcloned into the EcoRI site of
the pIRES2-Met.Luc vector under control of the cytomegalo-
virus promoter. For Western blot detection, a HPC4 tag was
fused to the C-terminus of all the VKORHs and VKORC1. To
localize the expression of VKORC1 and its homologues, a GFP
tag was introduced to the C-terminus of the protein with a
(GGSGG)6 flexible linker. To create the N-linked glycosylation
site in the first periplasmic loop of Mt-VKORH, residues P61
and I62 were mutated to S61 and T62, respectively. Together
with residue N60, this introduces an Tripeptide Asn-Ser-Thr of
N-Linked glycosylation consensus site (NST) sequence be-
tween the pair cysteines C57 and C65. Due to the short car-
boxyl terminus of Mt-VKORH and the requirement of at least
12 amino acid residues between the glycosylation site and the
membrane interface (20), an N-linked glycosylation consensus
sequence (NST) with a flexible extension linker (GGSGGSGGS)
was introduced at the carboxyl terminus of Mt-VKORH. All
the constructs for glycosylation studies have a HPC4 tag at
their carboxyl terminus for Western blot detection.
In vivo VKOR and VKR activity assay
VKOR and VKR in vivo activity was determined with our
cell-based assay as described previously (31). It is based on the
FIG. 8. Proposed reaction
mechanism of Mt-VKORH
in the reduction of ubiquinone
and vitamin K. (A) Proposed
reaction mechanism of Mt-
VKORH in Escherichia coli pro-
tein disulfide bond formation.
When a nascent peptide folds to
a disulfide-linked mature pro-
tein, a disulfide bond in the ac-
tive site of DsbA is reduced to
two free cysteines. These cyste-
ines reduce the disulfide bond
of the conserved loop cysteines
(C57 and C65) of Mt-VKORH
and, in turn those sulfhydryls
participate in the intramole-
cular reduction of the CXXC
redox center. When ubiquinone
is reduced to ubiquinol by Mt-
VKORH, the CXXC active site
cysteines are oxidized back to a
disulfide bond. (B) Proposed
reaction mechanism of Mt-
VKORH for reducing vitamin K
in mammalian cells. The Mt-
VKORH disulfide bond of the
CXXC active site is directly re-
duced by an unknown reduc-
tant. The reduced form of the
enzyme can apparently reduce
both KO and vitamin K for
carboxylation in mammalian
cells.
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ability of VKORC1 or its homologue to convert sufficient KO to
vitamin K or vitamin K to KH2 in mammalian cells to support
the carboxylation of a reporter protein, FIXgla-PC. VKORHs or
warfarin-resistant VKORC1-Y139F was transiently expressed
into HEK293 or AV12 cell lines that stably express the reporter
protein in a 24-well plate. Metridia luciferase was coexpressed
as the internal control from the same mRNA transcript as
VKORC1 or VKORHs. Forty-eight hours posttransfection,
carboxylated FIXgla-PC in the cell culture medium was mea-
sured by ELISA (31). Luciferase activity was determined by
injecting 50 ll of coelenterazine solution (2 lM in PBS with
300 mM NaCl) to 50 ll of cell culture medium directly. Lumi-
nescence emission (relative light units [RLU]) from the mixture
was recorded at 480 nm with a delay of 6 s and integration time
of 1 s. VKOR or VKR activity was expressed as normalized
carboxylated FIXgla-PC (ng/ml/RLU). Mt-VKORH activity
was normalized to 100% unless otherwise stated. Before nor-
malization, carboxylated FIXgla-PC in the cell culture medium
varies from *80 to *200 ng/ml by transient expression of
wild-type Mt-VKORH. One-way analysis of variance was
used to assess significant differences as indicated. The crite-
rion for statistical significance was set as p < 0.05 or 0.001.
Western blot and confocal fluorescence microscope
To analyze the protein expression level and glycosylation
modification of Mt-VKORH, HPC4-tagged proteins were
transiently expressed in HEK293 cells. Forty-eight hours post-
transfection, cells were harvested and lysed in 300 ll PBS with
1% Triton X-100 in the presence of protease inhibitor cocktail.
For protein expression detection, the amount of cell lysate
loaded to SDS-NuPAGE was normalized by luciferase activity.
For deglycosylation, 1 ll PNGase F (500 U/ll) was added to a
50 ll aliquot of the cell lysate and incubated for 30 min at 37C.
Deglycosylated or nontreated samples were directly subjected
to SDS-NuPAGE under reducing condition. Western blot
analysis was performed as described previously (32).
For subcelluar localization of VKORC1 and its homo-
logues, GFP-tagged proteins were transiently expressed in
HEK293 cells in a chambered cover glass. Forty-eight hours
posttransfection, the chambered cover glass was placed di-
rectly on the microscope stage for image collection. Confocal
microscopy was performed on a Zeiss LSM710 confocal laser
scanning microscope (Carl Zeiss Microimaging, Thornwood,
NY). Images were collected using a 40X/1.2NA C-Apoc-
hromat objective lens. Visualization of the GFP was achieved
by use of a 488 nm Argon laser line for excitation and the
detector was set to collect emission at 493–530 nm.
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Abbreviations Used




FIXgla-PC¼protein C with its gla domain exchanged
with factor IX
GFP¼ green fluorescence protein




Mt-VKORH¼Mycobacterium tuberculosis vitamin K
epoxide reductase homologue
NST¼Tripeptide Asn-Ser-Thr of N-Linked
glycosylation consensus site
RLU¼ relative light units
Rs-VKORH¼Roseiflexus sp. RS-1 vitamin K epoxide
reductase homologue
SDS-NuPAGE¼ sodium dodecyl sulfate neutral
polyacrylamide gel electrophoresis
Ss-VKORH¼ Synechococcus sp. vitamin K epoxide
reductase homologue




VKOR¼ the reduction of vitamin K epoxide
to vitamin K
VKORC1¼vitamin K epoxide reductase
complex, subunit 1
VKORH¼vitamin K epoxide reductase
homologue
VKR¼ the reduction of vitamin K to KH2
338 TIE ET AL.
